CN1167703C - 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 - Google Patents
氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 Download PDFInfo
- Publication number
- CN1167703C CN1167703C CNB01808821XA CN01808821A CN1167703C CN 1167703 C CN1167703 C CN 1167703C CN B01808821X A CNB01808821X A CN B01808821XA CN 01808821 A CN01808821 A CN 01808821A CN 1167703 C CN1167703 C CN 1167703C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- hydrochloride
- free base
- acid addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0010955.3A GB0010955D0 (en) | 2000-05-05 | 2000-05-05 | Organic compounds |
| GB0010955.3 | 2000-05-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1427840A CN1427840A (zh) | 2003-07-02 |
| CN1167703C true CN1167703C (zh) | 2004-09-22 |
Family
ID=9891092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB01808821XA Expired - Fee Related CN1167703C (zh) | 2000-05-05 | 2001-05-03 | 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6780861B2 (enExample) |
| EP (1) | EP1282620B1 (enExample) |
| JP (1) | JP4898062B2 (enExample) |
| KR (1) | KR20020093974A (enExample) |
| CN (1) | CN1167703C (enExample) |
| AR (1) | AR028073A1 (enExample) |
| AT (1) | ATE263167T1 (enExample) |
| AU (2) | AU2001262257B2 (enExample) |
| BR (1) | BR0110521A (enExample) |
| CA (1) | CA2407972C (enExample) |
| CZ (1) | CZ20023622A3 (enExample) |
| DE (1) | DE60102581T2 (enExample) |
| DK (1) | DK1282620T3 (enExample) |
| ES (1) | ES2218418T3 (enExample) |
| GB (1) | GB0010955D0 (enExample) |
| HK (1) | HK1054223B (enExample) |
| HU (1) | HUP0301866A2 (enExample) |
| IL (1) | IL152417A0 (enExample) |
| MX (1) | MXPA02010892A (enExample) |
| NO (1) | NO20025280D0 (enExample) |
| NZ (1) | NZ522226A (enExample) |
| PE (1) | PE20020221A1 (enExample) |
| PL (1) | PL357435A1 (enExample) |
| PT (1) | PT1282620E (enExample) |
| RU (1) | RU2002131886A (enExample) |
| SK (1) | SK15612002A3 (enExample) |
| TR (1) | TR200401007T4 (enExample) |
| WO (1) | WO2001085727A1 (enExample) |
| ZA (1) | ZA200208969B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6262265A (ja) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | 復水器自動検査補修システム |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| PE20021019A1 (es) * | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| BR0213501A (pt) * | 2001-11-02 | 2004-08-24 | Searle Llc | Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US6852716B2 (en) * | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
| MXPA04008152A (es) * | 2002-02-19 | 2005-09-08 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
| DE10234424A1 (de) * | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| CN1735414A (zh) | 2002-12-06 | 2006-02-15 | 北岸长岛犹太人研究学院 | 用α7受体结合类胆碱激动剂抑制炎症 |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| MXPA05010496A (es) * | 2003-03-28 | 2005-11-16 | Pharmacia & Upjohn Co Llc | Moduladores alostericos positivos del receptor de acetilcolina nicotinico. |
| WO2005063767A2 (en) * | 2003-12-22 | 2005-07-14 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| US20050170360A1 (en) * | 2004-01-30 | 2005-08-04 | Papke Roger L. | Variant neuronal nicotinic alpha-7 receptor and methods of use |
| EP1713809B1 (en) | 2004-02-04 | 2009-07-29 | Neurosearch A/S | Dimeric azacyclic compounds and their use |
| US20050234095A1 (en) | 2004-03-25 | 2005-10-20 | Wenge Xie | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| JP2007534692A (ja) * | 2004-04-22 | 2007-11-29 | メモリー・ファーマシューティカルズ・コーポレイション | インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用 |
| US7632831B2 (en) * | 2004-05-07 | 2009-12-15 | Memory Pharmaceuticals Corporation | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| RU2418797C2 (ru) * | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| ES2541528T3 (es) | 2008-11-19 | 2015-07-21 | Forum Pharmaceuticals Inc. | Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| WO2010132423A1 (en) * | 2009-05-11 | 2010-11-18 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
| US20120157464A1 (en) * | 2009-07-23 | 2012-06-21 | Novartis Ag | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| JP5633405B2 (ja) * | 2010-02-18 | 2014-12-03 | Jsr株式会社 | 新規化合物、感放射線性組成物及び硬化膜 |
| JP5852094B2 (ja) * | 2010-03-26 | 2016-02-03 | コーニング インコーポレイテッド | 低非線形長距離用光通信システム |
| JP5749797B2 (ja) | 2010-05-17 | 2015-07-15 | フォルム ファーマシューティカルズ、インコーポレイテッド | （ｒ）−７−クロロ−ｎ−（キヌクリジン−３−イル）ベンゾ［ｂ］チオフェン−２−カルボキサミド塩酸塩一水和物の結晶形 |
| RU2013108223A (ru) | 2010-07-26 | 2014-09-10 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных нарушений определенными агонистами рецептора никотиновой кислоты альфа-7 в сочетании с ингибиторами ацетилхолинэстеразы |
| US20140171448A1 (en) | 2011-01-27 | 2014-06-19 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| UA118248C2 (uk) * | 2011-03-18 | 2018-12-26 | Джензім Корпорейшн | Інгібітори глюкозилцерамідсинтази |
| US20140228398A1 (en) | 2011-03-18 | 2014-08-14 | Novartis Ag | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
| CN103502213B (zh) * | 2011-04-29 | 2016-09-28 | 奇斯药制品公司 | 生物碱酯及其氨基甲酸酯衍生物和医学组合物 |
| BR112014007485B1 (pt) * | 2011-10-20 | 2022-05-31 | Novartis Ag | Métodos para prever responsividade terapêutica de um indivíduo a tratamento com um ativador do receptor de acetilcolina nicotínico alfa 7, e usos do referido ativador |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| CN104837499B (zh) | 2012-12-11 | 2018-02-23 | 诺华有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物 |
| CA2898080C (en) | 2013-01-15 | 2018-01-09 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| WO2014111837A1 (en) | 2013-01-15 | 2014-07-24 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| JP6137336B2 (ja) * | 2013-01-15 | 2017-05-31 | ノバルティス アーゲー | ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用 |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| US12083115B2 (en) | 2020-02-03 | 2024-09-10 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| BR112023000798A2 (pt) | 2020-07-24 | 2023-02-07 | Genzyme Corp | Composições farmacêuticas compreendendo venglustat |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| WO1995006635A1 (en) * | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| WO1996008468A1 (en) * | 1994-09-14 | 1996-03-21 | H. Lundbeck A/S | Carbamoyloxy amine compounds |
| GB9525261D0 (en) | 1995-12-11 | 1996-02-07 | Bayer Ag | Carbamic acid derivatives |
| GB9526560D0 (en) * | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6313247B1 (en) * | 1996-06-05 | 2001-11-06 | Wolfgang Lindner | Cinchonan based chiral selectors for separation of stereoisomers |
| US6525065B1 (en) * | 1997-06-30 | 2003-02-25 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| US6624173B1 (en) * | 1997-06-30 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions for treating and/or preventing CNS disorders |
| US5988429A (en) * | 1997-10-14 | 1999-11-23 | Pharmadesign, Inc. | Blister pack pill dispenser |
| AU782114B2 (en) * | 1999-09-28 | 2005-07-07 | Eisai R&D Management Co., Ltd. | Quinuclidine compounds and drugs containing the same as the active ingredient |
| WO2002016358A2 (en) * | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| GB0109871D0 (en) * | 2001-04-20 | 2001-06-13 | Glaxo Group Ltd | Metering method for particulate material |
-
2000
- 2000-05-05 GB GBGB0010955.3A patent/GB0010955D0/en not_active Ceased
-
2001
- 2001-05-03 PL PL01357435A patent/PL357435A1/xx not_active Application Discontinuation
- 2001-05-03 CZ CZ20023622A patent/CZ20023622A3/cs unknown
- 2001-05-03 JP JP2001582328A patent/JP4898062B2/ja not_active Expired - Fee Related
- 2001-05-03 HU HU0301866A patent/HUP0301866A2/hu unknown
- 2001-05-03 TR TR2004/01007T patent/TR200401007T4/xx unknown
- 2001-05-03 PT PT01936319T patent/PT1282620E/pt unknown
- 2001-05-03 PE PE2001000399A patent/PE20020221A1/es not_active Application Discontinuation
- 2001-05-03 AU AU2001262257A patent/AU2001262257B2/en not_active Ceased
- 2001-05-03 CA CA002407972A patent/CA2407972C/en not_active Expired - Fee Related
- 2001-05-03 DE DE60102581T patent/DE60102581T2/de not_active Expired - Lifetime
- 2001-05-03 KR KR1020027014760A patent/KR20020093974A/ko not_active Withdrawn
- 2001-05-03 DK DK01936319T patent/DK1282620T3/da active
- 2001-05-03 MX MXPA02010892A patent/MXPA02010892A/es unknown
- 2001-05-03 RU RU2002131886/04A patent/RU2002131886A/ru not_active Application Discontinuation
- 2001-05-03 US US10/258,920 patent/US6780861B2/en not_active Expired - Fee Related
- 2001-05-03 EP EP01936319A patent/EP1282620B1/en not_active Expired - Lifetime
- 2001-05-03 CN CNB01808821XA patent/CN1167703C/zh not_active Expired - Fee Related
- 2001-05-03 NZ NZ522226A patent/NZ522226A/en unknown
- 2001-05-03 BR BR0110521-3A patent/BR0110521A/pt not_active Application Discontinuation
- 2001-05-03 ES ES01936319T patent/ES2218418T3/es not_active Expired - Lifetime
- 2001-05-03 AR ARP010102089A patent/AR028073A1/es not_active Application Discontinuation
- 2001-05-03 IL IL15241701A patent/IL152417A0/xx unknown
- 2001-05-03 AU AU6225701A patent/AU6225701A/xx active Pending
- 2001-05-03 SK SK1561-2002A patent/SK15612002A3/sk unknown
- 2001-05-03 HK HK03104830.3A patent/HK1054223B/en not_active IP Right Cessation
- 2001-05-03 AT AT01936319T patent/ATE263167T1/de active
- 2001-05-03 WO PCT/EP2001/005008 patent/WO2001085727A1/en not_active Ceased
-
2002
- 2002-11-04 NO NO20025280A patent/NO20025280D0/no not_active Application Discontinuation
- 2002-11-05 ZA ZA200208969A patent/ZA200208969B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1167703C (zh) | 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 | |
| AU2001262257A1 (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | |
| ES2639196T3 (es) | Método para preparar silodosina | |
| US8084487B2 (en) | Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof | |
| CN1011784B (zh) | 制备抗过敏和抗支气管痉挛药n-二苯甲基二氮杂环烷基烷基n-酰苯胺的方法 | |
| CN1183136C (zh) | 吲哚并喹唑啉酮 | |
| CN1659170A (zh) | 噻吩基化合物 | |
| CN1066145C (zh) | N－取代的3－氮杂双环[3,2,0]庚烷衍生物及其制备方法和应用 | |
| CN1043574C (zh) | 具有中枢神经系统活性的杂环胺 | |
| CN1230959A (zh) | N－(2－苯并噻唑基)－1－哌啶乙胺衍生物,其制备方法及其在治疗中的应用 | |
| CN1255130A (zh) | 化合物 | |
| CN1582282A (zh) | 新颖的取代的四环系四氢呋喃衍生物的扁桃酸盐化合物 | |
| CN1146992A (zh) | 中间体(r)-3-氨基-5-甲氧基苯并二氢吡喃的制备方法 | |
| CN1210262C (zh) | 1－(4－羟苯基)－2－(4－羟基－4－苯基哌啶－1－基)－1－丙醇的甲磺酸盐三水合物的制备方法 | |
| EP1873139A1 (fr) | Nouveaux dérivés naphtaleniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| CN1133288A (zh) | 具有1-(芳基链烯基)-4-(芳基甲基)哌嗪结构的新化合物，其制备方法及含这类化合物的药物组合物 | |
| CA2015665A1 (fr) | Derive d'hydroxyphenethylamine et ses sels, procede de preparation, application a titre de medicaments et utilisation comme outil pharmacologique specifique | |
| JP2001354650A (ja) | １−（４−ヒドロキシフェニル）−２−（４−ヒドロキシ−４−フェニルピペリジン−１−イル）−１−プロパノールのメシル酸塩三水和物の調製方法及びそのために有用な中間体 | |
| TW201116512A (en) | New piperidine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| CN1120042A (zh) | 取代1-(7-氯喹啉-4-基)吡唑-3-甲酰胺n-氧化物衍生物，其制备方法及药物组合物 | |
| CN101061117A (zh) | 新的萘基取代的氮杂双环衍生物和它们作为单胺神经递质再摄取抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040922 Termination date: 20160503 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |